MIT Novo Nordisk Postdoctoral Fellow · MIT
MIT Laboratory for Translational Engineering (L4TE) · MIT Novo Nordisk AI Fellowship
AI-driven drug discovery, targeted therapeutic design, and next-generation drug delivery platforms.
Dr. Alper Karagöl is a medical doctor (MD, Istanbul University, 1st place in English Medical Program) and MIT Novo Nordisk Postdoctoral Fellow at the MIT Laboratory for Translational Engineering (L4TE).
His research identifies and validates novel drug targets and engineers environment-responsive, peptide-based therapeutic candidates for neurological, hematological, inflammatory, and oncological disease—supported by a portfolio of over 85 publications and manuscripts, featured journal cover art, 3 patent applications, and 15 open-source computational biology tools.
MIT Laboratory for Translational Engineering (L4TE) · MIT Novo Nordisk AI Fellowship
AI-driven drug discovery, targeted therapeutic design, and next-generation drug delivery platforms.
Clinical Trials Research Team & Medical Elective (Guy's & St Thomas' NHS Trust — Rheumatology)
Big data clinical analysis, Hidden Markov Modeling of epidemiological trajectories, and pharmacoeconomics.
Laboratory of Molecular Architecture, MIT Media Lab
Alternative mRNA splicing of neurotransmitter transporters, heteromerization and modulator design, MSA-based structure prediction, QTY-code membrane protein engineering, and evolutionary game theory.
Structural Immunology Group, Darwin Building · UCL Medical School & UCLH NHS Foundation Trust
Structural alterations and mutational epistasis in coagulation factors (Factor IX), human genetic variant profiling, and MySQL/web clinical database architecture.
Beth Israel Deaconess Medical Center, Boston
Clinical & surgical observerships spanning Neurosurgery, Interventional Neuroradiology, Head & Neck Oncological Surgery, Otolaryngology, and Stroke Neurology.
Istanbul Faculty of Medicine, English Program
Admitted 1st place in cohort (Top 0.015% nationally on YKS, 350 / 2.38M); Dean's Award for Scientific Excellence (2025) and Outstanding Achievement Award in Medical Sciences (2026).